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Abstract: Heart failure with normal ejection fraction (HeFNEF) accounts for ~50% of heart 
failure admissions. Its pathophysiology and diagnostic criteria are yet to be defined clearly 
which may hinder the search for effective treatments. The clinical hallmark of HeFNEF is exer-
tional breathlessness, often due to an abnormal increase in left atrial pressure during exercise. 
Creation of an interatrial communication to offload the left atrium is a possible therapeutic 
approach. There are two percutaneously delivered devices currently under investigation which 
are discussed in this review. 
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Introduction
Heart failure with normal ejection fraction (HeFNEF) accounts for ~50% of heart 
failure diagnoses,1,2 yet the underlying pathophysiology and diagnostic criteria are 
poorly defined.3–5 Partly as a consequence, no medical treatment has yet shown con-
vincing outcome benefit for patients with HeFNEF.6–8 There is a clear unmet need for 
effective treatments for patients with HeFNEF. Implantable devices, such as cardiac 
resynchronisation therapy (CRT), improve symptoms and life expectancy in a subset 
of patients with heart failure and reduced ejection fraction (HeFREF).9 Some others 
allow early adjustment of medical therapy to avoid hospitalizations by monitoring 
cardiac haemodynamics.10 However, trials exploring the role of implantable devices 
such as CRT and rate-adaptive pacing in patients with HeFNEF have stalled, mainly 
due to recruitment failure,11–13 perhaps reflecting a reluctance of older patients with 
several comorbidities to participate.  
The clinical hallmark of HeFNEF is exertional breathlessness, at least in part due 
to an abnormal increase in left atrial pressure (LAP) during exercise.14,15 In patients 
with severe pulmonary artery hypertension (PAH), creation of a right to left atrial shunt 
reduces right atrial and ventricular pressures and improves symptoms,16–19 possibly due 
to increased systemic oxygen delivery due to increased cardiac output despite increas-
ing cyanosis.20 Decompressing the left atrium might similarly provide symptomatic 
and haemodynamic improvement in patients with HeFNEF. 
Reducing LAP with a percutaneously delivered atrial septal device is a novel 
potential therapeutic strategy. This review summarizes the potential clinical implica-
tions of reducing LAP with an interatrial shunt device in patients with HeFNEF21–23 
and discusses the preliminary results of the clinical trials conducted so far.
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Consequences of changing LAP
There are many potential mechanisms leading to reduced 
exercise tolerance in patients with HeFNEF.14,24,25 In normal 
physiology, increased stroke volume during exercise is 
accomplished in part by the positive lusitropic consequence 
of sympathetic activation: left ventricular (LV) relaxation 
is enhanced with lower LV pressure in early diastole.26,27 
Impaired LV relaxation and increased LV stiffness in patients 
with HeFNEF prevents an increase in end diastolic LV vol-
ume during exercise,28,29 thus increasing pressure in the left 
atrium.3 The excessive increase in LAP, measured by pulmo-
nary capillary wedge pressure (PCWP), during exercise is a 
common finding in patients with HeFNEF14,15,29 and identifies 
those with a worse prognosis.30,31 
Although patients with HeFNEF reach a lower peak work-
load (watts per kilogram of body weight) during incremental 
exercise tests compared with normal controls, both reach 
similar peak exercise PCWP.14 Increased workload-indexed 
peak exercise PCWP may be diagnostic of early-stage HeF-
NEF.14 A higher ratio of peak exercise PCWP to workload is 
associated with increased risk of 10-year mortality in patients 
with HeFNEF.31  
Surgical and medical interventions that alter LAP might 
have a significant impact on symptoms and mortality in vari-
ous cardiac pathologies. One example is that a device making 
invasive measurement of LAP as a guide for medical therapy 
in patients with HeFREF (n=40) was associated with reduced 
LAP, improved symptoms, and reduced rates of worsening 
symptoms requiring intravenous diuretic therapy.32
In an observational study of 5 patients with high LAP 
and lower right atrial pressure (RAP) as a result of congenital 
obstructive left heart defects, the creation of an interatrial 
communication alleviated left atrial hypertension and 
improved symptoms.33 Conversely, pulmonary edema can 
develop in some patients secondary to dramatic increases in 
LAP following closure of an atrial septal defect (ASD).34,35 
Two devices, the V-Wave® (V-Wave Ltd, Or Akiva, Israel) 
and IASD® (DC Devices Inc., Tewksbury, MA, USA) have 
been tested in patients with heart failure (Table 1).22,23,36–41
V-Wave device
The V-Wave device is a tri-leaflet porcine tissue valve on an 
hourglass-shaped nickel-titanium frame (Figure 1).36 The 
device is implanted via a femoral venous approach under 
general anesthetic with fluoroscopic and trans-esophageal 
echocardiography (TOE) guidance.22 Following radiofre-
quency trans-septal puncture, the center of the hourglass (5 mm 
diameter) is placed across the fossa ovalis with the ends of the 
hourglass sitting in left and right atria securing the device in 
place.22 The left atrial orifice is lined with expanded polytet-
rafluoroethylene (ePTFE) designed to improve blood flow 
and restrict new tissue growth over the device.22 Blood flows 
from the left to right via the porcine valve which is designed 
to close when RAP exceeds 2 mmHg, thus preventing right to 
left shunting.22 After device implantation, patients require anti-
coagulation with warfarin or direct-acting oral anticoagulant 
(DOAC) for 3 months and with low-dose aspirin indefinitely.22
A proof-of-principle study was conducted in a single 
center in Canada, in patients with heart failure and reduced 
ejection fraction. They had raised PCWP (≥15 mmHg) with-
out substantial right ventricular dysfunction (n=10; average 
age 62 years; average left ventricular ejection fraction (LVEF) 
25%; average PCWP 23 mmHg; and average NTproBNP 
2712 pg/mL).36 After 3 months, insertion of the device was 
associated with a reduction in New York Heart Association 
(NYHA) class, increased 6-minute walk test distance, and 
improved quality of life (QoL) and physical function assessed 
by Kansas City cardiomyopathy questionnaire and Duke 
activity status index.36 Device implantation was associated 
with a modest decrease in LV volumes and PCWP (23 mmHg 
pre-procedure to 17 mmHg at 3 months; p=0.035); however, 
natriuretic peptides (NPs), RAP (9 vs 8 mmHg at 3 months; 
p=0.18), and mean pulmonary artery pressure (29 vs 26 
mmHg at 3 months, p=0.37) were unchanged.36
A preliminary case report demonstrated the feasibility and 
safety of the V-Wave device in a patient severely symptomatic 
with HeFNEF and a history of ischemic heart disease and 
atrial fibrillation (AF) (PCWP 22 mmHg, LVEF 50%, tak-
ing 240 mg of furosemide per day).39 Device insertion was 
associated with improved symptoms (NYHA III at baseline 
vs II at 6 months), functional capacity (6-minute walk test 
distance 281 m at baseline vs 617 m at 6 months), and a 
substantial drop in NTproBNP (2983 pg/mL at baseline vs 
1334 pg/mL at 6 months).39 
A further prospective, nonrandomized, open label, multi-
center study of the device is planned in patients with both 
HeFREF and HeFNEF (NCT02511912) (Table 2).42
IASD device
The interatrial shunt device (IASD) differs from the V-Wave 
device in three ways: first, the device does not incorporate 
valve tissue; second, the inter-atrial communication is larger (8 
mm diameter compared with 5 mm with the V-Wave device); 
third, the device is a bare metal and not coated with ePTFE. 
Instead, the left atrial side of the device is flush with the atrial 
tissue to reduce the risk of thrombus formation (Figure 2).23 
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Table 1 Summary of trials of interatrial shunt devices
Trial Device Study design n Inclusion/exclusion criteria Patient characteristics Results
Del Trigo et al36 V-Wave® Prospective
Single-arm
Nonrandomized
Un-blinded
10 Inclusion
•	 ≥18 years of age
•	 ≥6 month history of HF
•	 NYHA III or IV
•	 On optimal medical and device 
therapy
•	 LVEF ≤40%
•	 Severe RVSD
•	 PCWP ≥15 mmHg
Exclusion
•	 Cerebrovascular or 
thromboembolic event in the 
last 6 months
•	 Coagulation disorders or 
contraindications for oral 
anticoagulation
•	 Left atrial or ventricular 
thrombus
•	 PASP >70 mmHg
Average age: 62 years
Average LVEF: 25%
Average PCWP: 
23 mmHg
Average NTproBNP: 
2712 pg/mL
•	 No serious adverse device 
events after 3 months
•	 Reduction in NYHA class, 
increased 6MWT distance, 
improved QoL and physical 
functional status after 3 
months
•	 Reduction in mean PCWP 
(23–17 mmHg) after 3 
months (p=0.035)
•	 NTproBNP unchanged from 
baseline to 3 months 
Sondergaard 
et al23
Malek 
et al37 – 1-year 
follow-up
IASD® Prospective. 
Single-arm. 
Nonrandomised. 
Un-blinded.
11 Inclusion
•	 ≥1 HF hospitalisation in the 
last year or persistent NYHA 
class III or IV symptoms for 
3 months.
•	 ≥40 years of age
•	 LVEF ≥45%
•	 Dilated LA indexed for body 
size without more than mild 
mitral valve disease
•	 PCWP ≥15 mmHg at rest or 
≥25 mmHg during exercise.
•	 HR ≤90 bpm if in AF
•	 On stable medical therapy: on 
diuretics for ≥2 months and 
no changes to cardiovascular 
medications in ≤2 weeks prior 
to enrolment.
Exclusion
•	 Prior history of 
cerebrovascular or 
thromboembolic events
•	 Left atrial thrombus
•	 Valve disease worse than mild
•	 Significant LV wall motion 
abnormalities
•	 RVSD
•	 Estimated PASP >60 mmHg
•	 Restrictive or obstructive lung 
disease worse than mild.
•	 >70% coronary artery stenosis 
untreated or ACS within 
3 months of enrolment.
•	 Contraindications to dual 
antiplatelet therapy or oral 
anticoagulation
Average age: 71 years
Average LVEF: 57%
Average PCWP: 
19 mmHG
Median NTproBNP: 
148 pg/mL
•	 No serious adverse device 
events after 30 days
•	 One hospitalization with 
worsening HF after 30 days
•	 28% reduction in mean 
PCWP after 30 days 
(p=0.005)
•	 NYHA, 6MWT, and QoL 
assessment improvements 
after 30 days follow-up
•	 Improvement in NYHA class 
sustained after 1 year but 
improvements in 6MWT and 
QoL assessment were no 
longer statistically significant
•	 No change in NTproBNP at 
any time point
(Continued)
 
M
ed
ica
l D
ev
ice
s:
 E
vid
en
ce
 a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
10
6 
on
 0
5-
Ja
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Medical Devices: Evidence and Research 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
126
Cuthbert et al
The first in man experience of IASD was a nonrandomized, 
unblinded, feasibility study in patients with HeFNEF and base-
line PCWP ≥15 mmHg at rest or ≥25 mmHg during exercise 
(n=11, average age 71 years; average LVEF 57%; median 
NTproBNP 148 pg/mL; average PCWP 19 mmHg).23 Device 
implantation was associated with reduction in mean PCWP 
(by 28%, from 19+5 to 14+3 mmHg, p=0.005) after 30 days 
alongside symptomatic, functional, and QoL improvements.23 
NTproBNP plasma levels did not significantly change.23 
Devices were successfully implanted in all but one patient in 
whom device malpostion was corrected by the insertion of 
a new device. There were no reports of device-related com-
plications such as migration or loss of patency (although in 
one patient the direction of flow could not be detected) after 
30 days follow up.23 During the same period, one patient was 
admitted with acute heart failure.23 At 1 year, all patients sur-
vived and symptomatic improvement (measured by NYHA 
class) was sustained, although some patients required an 
increase in their daily dose of loop diuretics.37 
REDUCE LAP-HF trial
The REDUCE LAP-HF trial was an open-label, nonrandom-
ized phase 1 study of the IASD in patients with HeFNEF 
and raised PCWP (≥15 mm at rest or ≥25 mmHg during 
exercise).38 A total of 68 patients were enrolled in 21 centers, 
with an average age of 69 years. Average LVEF was 47% and 
mean PCWP at rest was 17 mmHg; median NT-pro-BNP 
Table 1 (Contined)
Trial Device Study design n Inclusion/exclusion criteria Patient characteristics Results
REDUCE 
LAP-HF38,40,41
IASD Prospective. 
Single-arm. 
Multi-centre. 
Open-label.
Nonrandomised.
Un-blinded.
68 Inclusion
•	 ≥40 years of age
•	 NYHA III or IV and/or 
1 HF hospitalisation and/
or treatment with guideline 
directed therapies within 
12 months of enrolment
•	 LVEF ≥40%
•	 Mean PCWP ≥15 mmHg at 
rest or ≥25 mmHg during 
exercise.
Exclusion
•	 ACS within 3 months of 
enrolment
•	 CRT within 6 months of 
enrolment
•	 Severe HF
•	 Cerebrovascular or 
thromboembolic event within 
6 months of enrolment
•	 Significant valvular disease
•	 RVSD
•	 AF with resting HR >100 bpm
•	 Intracardiac vegetation, mass 
or thrombus
•	 eGFR <25 mL/min
•	 Systolic BP >170 mm Hg 
Average age: 69 years
Average LVEF: 47%
Average PCWP: 
17 mmHg
Median NTproBNP: 
377 pg/mL 
•	 94% success rate of index 
procedure
•	 No incidence of serious 
adverse events after 
6 months
•	 Reduced rest or exercise 
PCWP in 71% of patients 
after 6 months
•	 Reduced workload-indexed 
PCWP after 6 and 12 months 
in subgroup analysis (n=18); 
however, no change in 
average rest or exercise 
PCWP after 6 or 12 months 
in the same group
•	 Improvement in NYHA 
class, 6MWT distance, and 
QoL assessment after 6 and 
12 months
•	 Device patency with left–
right shunt after 12 months 
confirmed in all patients with 
adequate images (n=48)
•	 No change in NTproBNP 
after 6 or 12 months
Abbreviations: HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; RVSD, right ventricular systolic dysfunction; PCWP, 
pulmonary capillary wedge pressure; PASP, pulmonary artery systolic pressure; NTproBNP, N-terminal B-type natriuretic peptide; 6MWT, 6-minute walk test; QoL, quality 
of life; LA, left atrium; HR, heart rate; AF, atrial fibrillation; LV, left ventricle; ACS, acute coronary syndrome; CRT, cardiac resynchroniozation therapy; eGFR, estimate 
glomerular filtration rate; BP, blood pressure.
Figure 1 The V-Wave® interatrial shunt device.
Note: Reprinted from Lancet, 387, Del Trigo M, Bergeron S, Bernier M, et al, 
Unidirectional left-to-right interatrial shunting for treatment of patients with heart 
failure with reduced ejection fraction: a safety and proof-of-principle cohort study, 
1290–1297, Copyright (2016), with permission from Elsevier.36
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Table 2 Summary of future trials of interatrial shunt devices
Trial Device Study design Estimated 
enrollment
Inclusion/exclusion criteria Outcome measures
RELIEVE-HF42 V-Wave® Prospective
Single-arm
Multicenter
Nonrandomized
Unblinded
60 Inclusion:
•	 NYHA III or IV taking optimal medical 
therapy 
•	 LVEF ≥15%
Exclusion:
•	 RVSD
•	 RAP > LAP
•	 Congenital heart disease
•	 Severe pulmonary hypertension
•	 Severe restrictive or obstructive lung 
disease
•	 Device-related MACCE within 
6 months of device implantation
•	 Changes in 6MWT after 6 months
•	 Overall MACCE after 12 months
REDUCE 
LAP-HFREF68
IASD® Prospective 
Single-arm
Nonrandomized
Un-blinded
10 Inclusion:
•	 NYHA III or IV and signs of pulmonary 
congestion (rales, chest X-ray findings) 
and ≥1 HF hospitalization in last 
12 months
•	 Stable optimal medical, device, and 
surgical therapy for 6 months
•	 ≥18 years of age
•	 LVEF 20%–40% on echocardiography
•	 Resting PCWP ≥18 mmHg and PCWP 
greater than RAP by ≥5 mmHg 
Exclusion:
•	 NTproBNP <100 pmol/L in SR or 
<300 pmol/L in AF
•	 MI, PCI, or CABG in previous 3 months
•	 ICD or CRT in previous 3 months
•	 Severe HF 
•	 6MWT >600 m
•	 Cerebrovascular or thromboembolic 
disease <6 months
•	 Significant valve disease
•	 Contraindication to dual antiplatelet or 
anticoagulant therapy
•	 AF with HR >100 bpm
•	 Resting RAP >14 mmHg
•	 RVSD
•	 Systolic BP >170 mmHg
•	 Peri-procedural and 6-month 
MACCE and systemic embolic 
events
•	 Percentage of patients who have 
successful device implantation 
during index procedure
•	 Percentage of patients with left–
right flow through the device
Abbreviations: NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; RVSD, right ventricular systolic dysfunction; RAP, right atrial pressure; LAP, 
left atrial pressure; MACCE, major adverse cardiac and cerebrovascular events; 6MWT, 6-minute walk test; HF, heart failure; PCWP, pulmonary capillary wedge pressure; 
NTproBNP, N-terminal B-type natriuretic peptide; SR, sinus rhythm; AF, atrial fibrillation; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass graft; ICD, implantable cardio-defibrilator; CRT, cardiac resynchroniozation therapy; HR, heart rate; BP, blood pressure.
was 377 pg/mL (interquartile range 222–925 pg/mL).40 The 
co-primary endpoints were the proportion of patients with 
successful device implantation, reduction in PCWP at rest 
and during exercise after 6 months, and evidence of a left–
right shunt on echocardiography at the same time point.40 
Procedure and short-term safety 
outcomes
Procedural complication rate was 5 in 66 initial procedures: 
3 patients required removal of the initial device (misplace-
ment n=2; suspected right atrial thrombus n=1). All the 3 
patients subsequently underwent uncomplicated insertion 
of a second device. Two procedures had to be abandoned 
and were not repeated (one due to complications following 
trans-septal puncture and another due to unsuitable atrial 
anatomy). Overall, the device was successfully implanted 
in 64 patients (94%).40 
All the patients received dual antiplatelet therapy with 
aspirin and clopidogrel post procedure. In the first 6 months, 
there were no major adverse events, such as stroke, myocar-
dial infarction, pulmonary or systemic embolism, or surgical 
intervention for device-related complications.40 Left to right 
blood flow through patent devices was confirmed at 6 months 
in all patients who had adequate images (n=50).40 
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Hemodynamic outcomes
After 6 months, IASD implantation was associated with 
reduced PCWP at rest in 52% of patients (n=32) and reduced 
PCWP measured by right heart catheterization during supine 
bicycle exercise in 58% of patients (n=34). The device was 
associated with reduced rest or exercise PCWP in 71% of 
patients (n=42) and reduced rest and exercise PCWP in 39% 
of patients (n=23).40 However, hemodynamic testing in a 
subset of patients at 12 months (n=18) showed no difference 
in average rest or exercise PCWP or RAP between baseline, 
6 months, and 12 months.41 Despite this, IASD insertion 
was associated with reduction in workload-indexed PCWP 
at peak exercise from baseline to 6 months (p≤0.05) which 
was sustained at 12 months (p≤0.01) (Figure 3).41 
QoL and symptom outcomes
Insertion of the IASD was associated with significant 
improvements in symptoms, QoL, and functional status 
at 6 months which were sustained at 12 month follow-up: 
NYHA class (p≤0.001 at 6 and 12 months compared to 
baseline), QoL score (p≤0.001), and 6-minute walk distance 
(p≤0.01) all improved (Figure 4).41 
Long-term safety of IASD
Of the 64 patients who had the device implanted, 3 patients 
(5%) died between 6- and 12-month follow-up; 1 death was 
due to stroke, 1 due to pneumonia, and in 1 the cause was 
undetermined.41 There were 17 HF hospitalizations among 13 
patients in the year post implantation, 10 of which occurred 
in 10 patients in the first 6 months.41 Left–right shunt through 
a patent device was confirmed on echocardiography at 
12 months in all patients with good-quality images (n=48).41 
Introduction of a left–right atrial shunt with the IASD was 
associated with an increase in the right ventricular volume 
and ejection fraction, but not RAP compared to baseline.41 
There was no effect on LVEF and left atrial volume, although 
LV diastolic volume decreased.41 
Pulmonary artery oxygenation increased from 69% 
to 75% at 6 month follow-up (p≤0.0001) confirming the 
presence of a left–right shunt, but was not reported at 
12 months.40,41 Although oximetry was used to measure LV 
output (which remained unchanged at 6 and 12 months), 
measures of systemic oxygenation were not reported at 6 or 
12 months.40,41 
Limitations of REDUCE LAP-HF
Creation of a left–right atrial shunt with either the V-Wave 
or IASD seems feasible and safe in the mid-term and may 
cause symptomatic improvement in some carefully selected 
patients with heart failure and raised LAP. However, caution 
is required when interpreting the available data. 
•	 Around one third of the patients had AF,40 in which case 
PWCP might vary beat to beat. It is not clear whether 
one-off readings can be considered accurate or whether 
an average reading from a specific number of cardiac 
cycles was used instead. 
•	 The change in PCWP (a designated primary outcome) was 
not significant unless indexed for a subjective, patient-
dependent variable such as exercise workload. 
•	 The investigators reported a decrease in the difference 
between LAPs and RAPs (reduced PCWP-RAP gradi-
ent) which, in fact, would have meant an increased RAP/
PWCP ratio.40,41 Increased RAP/PCWP ratio is associated 
with poorer long-term outcome in hospitalized patients 
with advanced HeFREF (LVEF <30%),43 but the clinical 
importance of this in HeFNEF is not yet known.
Figure 2 Expanded IASD® device.
Note: Copyright © 2014. John Wiley and Sons. Reproduce from Søndergaard L, 
Reddy V, Kaye D, et al. Transcatheter treatment of heart failure with preserved or 
mildly reduced ejection fraction using a novel interatrial implant to lower left atrial 
pressure. Eur J Heart Fail. 2014;16:796–801.23
Figure 3 Bar graph showing workload-indexed peak exertion wedge pressure 
before and after interatrial shunt device placement (n=16).
Notes: Data are mean ± standard deviation. *p<0.05, **p<0.01 versus baseline. 
Reproduced from Kaye DM, Hasenfuss G, Neuzil P, et al. One-year outcomes 
after transcatheter insertion of an interatrial shunt device for the management of 
heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12):e003662. 
Available from http://circheartfailure.ahajournals.org/content/9/12/e003662.long.41
Abbreviations: PCWP, pulmonary capillary wedge pressure; M, months.
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•	 Many of the other measured outcomes were obtained 
through subjective tests in nonrandomized and unblinded 
participants and investigators. Outcomes such as QoL 
score, exercise time, and workload are subject to bias. 
Inevitably, there must be at least some placebo effect from 
undergoing a novel procedure involving general anesthesia.
•	 Improvement in NYHA class was mirrored by an increase 
in average 6-minute walk distance (331 m at baseline 
vs 363 m after 12 months, p=0.001).41 However, inter- 
and intra-observer NYHA class ascriptions are variable 
with low validity and reproducibility.44,45 Therefore, an 
improvement in exercise distance of an average 32 m may 
not be compatible with an improvement in NYHA class 
and may be due, instead, to a learning effect intrinsic to 
the test.46 
•	 HeFNEF was defined as the presence of symptoms and 
signs compatible with the diagnosis, a LVEF >40%, and 
PCWP >15 mmHg at rest or >25 mmHg during supine 
bicycle exercise on right heart catheterization. Although 
there are no universally accepted criteria to diagnose 
HeFNEF, some evidence suggests that there is no differ-
ence in resting and peak exercise PCWP between healthy 
controls, patients with hypertension, and patients with 
HeFNEF.14,47
•	 There were no data on the average or median systolic 
blood pressure of the participants in REDUCE LAP-HF 
or, indeed, any trial of V-Wave or IASD. A reduction in 
LAP can be achieved with commonly used heart failure 
medications, such as angiotensin-converting enzyme 
inhibitors (ACEi) or beta-blockers.32 The use of diuret-
ics, alone or in combination with an ACEi or angiotensin 
receptor blocker, improves symptoms and QoL in patients 
with HeFNEF.48 It cannot be known from the published 
data whether patients in whom the V-Wave or IASD was 
implanted were eligible for up-titration of their antihy-
pertensive medications as an alternative means to reduce 
LAP, although 70%–90% were hypertensive.23,36,40 Indeed, 
11 patients in REDUCE LAP-HF (17%) required an 
increased dose of diuretics during 6-month follow-up.40 
•	 The signs and symptoms of heart failure are notoriously 
nonspecific, and under-diagnosis and misdiagnosis of 
HeFNEF may be common.49–51 Serum NPs are the most 
powerful prognostic marker in HeFNEF,52,53 and raised 
levels are a diagnostic requirement.54 However, raised 
serum NPs were not an inclusion criteria for REDUCE 
LAP-HF.38 Patients with HeFNEF and low NP levels 
probably have a good prognosis and thus are unlikely to 
benefit from invasive intervention. Of those with higher 
Figure 4 Bar graph represents the effects of interatrial septal shunt device implantation on (A) NYHA class (n=60); (B) MLWHF (n=60); (C) 6MWD (n=55).
Notes: Data in B and C represent mean ± standard deviation. **p<0.01, ***p<0.001 versus baseline. Reproduced from Kaye DM, Hasenfuss G, Neuzil P, et al. One-year 
outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12):e003662. 
Available from http://circheartfailure.ahajournals.org/content/9/12/e003662.long.41
Abbreviations: NYHA, New York Heart Association; MLWHF, Minnesota Living with Heart Failure; 6MWD, 6-minute walk distance; M, months.
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NTproBNP plasma levels, the proportion who had 
echocardiographic evidence to support the diagnosis of 
HeFNEF (raised E/E’ ratio or augmented LV mass or left 
atrial volume),55 is not reported. Importantly, NP levels 
were not affected by device implantation.40,41 
Future perspective
The long-term effects of the IASD are unknown. A chronic 
left–right shunt increases pulmonary blood flow and may 
be well tolerated at younger ages: patients with ASD are 
at increased risk of PAH and atrial arrhythmias, but clini-
cal problems do not usually emerge until the fourth or fifth 
decade.56–65 However, in elderly individuals (the average 
age of patients in REDUCE LAP-HF was 69 years)40 with 
HeFNEF and altered ventricular compliance, left–right atrial 
shunts may cause increased pulmonary arterial pressure and 
subsequent right ventricular dysfunction. Such hemodynamic 
changes might affect other organs already compromised in 
HeFNEF, such as the kidneys,3 with a subsequent negative 
impact on long-term outcome. 
Another factor that may influence long-term outcome 
is the use of anticoagulation: IASD implantation required 
1-year dual antiplatelet therapy,23 whereas V-Wave implan-
tation required warfarin or DOAC for 3 months following 
implantation.22 Both the devices require indefinite, low-dose 
aspirin.22,23 A large proportion of patients with HeFNEF have 
AF and require anticoagulation anyway,3 which, in combina-
tion with aspirin, might increase bleeding risk. It is unclear 
whether, in patients with sinus rhythm, the anticoagulation 
required for either device is sufficient thrombo-prophylaxis or 
increases the risk of adverse events such as GI bleeding: one 
patient had a stroke during 12-month follow-up post IASD 
implantation,41 and one patient had a nonfatal gastrointestinal 
bleed during 3-month follow-up post V-Wave implantation.36 
Vigilance and caution will be required with future trials.
Finally, changing patient behavior due to study involve-
ment, known as the “Hawthorne effect,”66 may have 
influenced the results; possibly by increasing medication 
compliance during follow-up. In the absence of a control 
group with a sham procedure or blind readers, trials of 
V-Wave and IASD may be subject to the same bias that has 
been observed in trials of other invasive treatments, such as 
renal nerve denervation.67
Conclusion
HeFNEF remains an ill-defined clinical entity, which has 
lead, in part, to the failure to find effective treatment for the 
condition. Devices that can directly reduce LAP seem to be 
safe in the short- and mid-term, but there are no data on their 
long-term safety and efficacy. 
Sham-controlled randomized trials would blind a patient 
to treatment, reducing the risk of bias which necessarily 
affects measures with a large subjective influence such as 
6-minute walk distance or exercise workload. However, the 
practicalities may be difficult: the presence of a device would 
be easily spotted by an investigator during right heart cath-
eterization or echocardiography. Careful selection of relevant 
endpoints (such as changes in symptoms) in patients blind 
to treatment (with a sham procedure) should be assessed by 
physicians also blinded to treatment.
Such a trial is essential to confirm that the benefits 
reported from unblinded studies are real. It is also unclear 
whether similar reductions in LAP sufficient to improve 
symptoms may be achievable with pharmacotherapy in 
patients with HeFNEF. Care must be taken with future trials 
(Table 2) to ensure that there is no bias leading to misinter-
pretation of efficacy.
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